Peroxitech Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Peroxitech Therapeutics - overview
Location
Philadelphia, PA, US
Primary Industry
Biotechnology
About
Based in Pennsylvania, US, and founded by Aron Fisher, Sheldon I. Feinstein, and Thomas Han (CEO), Peroxitech Inc. , doing business as Peroxitech Therapeutics is a biopharmaceutical company that develops PIP-2 to repair and reverse acute lung injury (ALI) by addressing the cytokine storm cascade pathway. In May 2021, Peroxitech Therapeutics raised Seed funding led by investor Xontogeny, LCC.
The company creates biopharmaceuticals based on its lead molecule, PIP-2, which helps to reduce reactive oxygen species (ROS) buildup in the lungs resulting from respiratory failure with hypoxemia and tissue acidosis, as well as to treat acute lung injury. The company intends to use the May 2021 funding to advance the new treatment of acute lung injury and additional toxicology preclinical trials.
Current Investors
Xontogeny, LLC, Perceptive Advisors
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.peroxitech.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.